Canagliflozin vs Enavogliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Canagliflozin · Invokana
Marketed by Johnson & Johnson and partners
NCT01032629 · Phase 3 · completed
The trial randomized 4,330 participants to canagliflozin or placebo with quadruple masking and used a hard clinical primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Results were discordant across the prespecified comparisons: the 300-mg dose met the endpoint comparison, while the 100-mg dose and combined canagliflozin analysis did not.
Next expected readout: December 2026 · NCT05427084 (registry estimate)
Reported efficacy
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 (Baseline (Day 1) and Week 26); Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) (Baseline (Day 1) up to 30 days post last dose at Week 52 (up to Week 56)): Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002). (met)
Result source: NCT03170518
Enavogliflozin · Envlo
Marketed by Daewoong Pharmaceutical and partners
NCT04634500 · Phase 3 · completed
This Phase 3 trial randomly assigned 200 people with type 2 diabetes to enavogliflozin or to dapagliflozin, with participants and investigators unaware of assignment. It was designed to show enavogliflozin was not worse than dapagliflozin at lowering HbA1c over 24 weeks, within a margin of 0.35 percentage points. It met that test: HbA1c fell by 0.80 percentage points on enavogliflozin against 0.75 on dapagliflozin, a difference of 0.04 points (95% CI -0.21 to 0.12).
Next expected readout: December 2026 · NCT06399835 (registry estimate)
Reported efficacy
Change from baseline in HbA1c (at 24 weeks): Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35% (met)
Result source: NCT04634500
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Canagliflozin | Enavogliflozin |
|---|---|---|
| HbA1c, change | -0.4% vs 0.4%−0.8 vs placeboNCT0317051841 other results
| -0.8% vs -0.8%avs dapagliflozinNCT04634500 |
| Body weight, change (kg) | -2.9 vs -0.8−2.1 vs placeboNCT006422788 other results
| —Not posted · NCT05376969 |
| HbA1c below 7% | 42.8% vs 43%vs Metformin XRNCT018093276 other results
| —Not posted · NCT05376969 |
| Fasting plasma glucose, change | -0.6 vs 0.2−0.7 vs placeboNCT0103262934 other results
| —Not posted · NCT05376969 |
| 3-point MACE (% with event) | —Not posted · NCT04304261 | —Not posted · NCT05376969 |
HbA1c, change
- Canagliflozin
- -0.4% vs 0.4%−0.8 vs placeboNCT03170518
41 other results
- -0.7% vs -0.0% NCT01106651
- -0.4% vs -0.0% NCT01064414
- -1.0% vs -0.3% NCT01106690
- -1.1% vs -0.1% NCT01106625
- -1.0% vs 0.1% NCT01081834
- -1.1% vs -0.5% NCT01381900
- -0.6% vs -0.0% NCT01106651
- -0.3% vs -0.0% NCT01064414
- -0.9% vs -0.3% NCT01106690
- -0.8% vs -0.1% NCT01106625
- -0.8% vs 0.1% NCT01081834
- -1.0% vs -0.5% NCT01381900
- -1.0% vs -0.1% NCT02354235
- -1.4% vs -1.3% NCT01809327
- -0.9% vs -0.8% NCT01106677
- -0.9% vs -0.8% NCT00968812
- -1.0% vs -0.7% NCT01137812
- -1.4% vs -1.3% NCT01809327
- -0.8% vs -0.8% NCT01106677
- -0.8% vs -0.8% NCT00968812
- -1.8% vs -1.3% NCT01809327
- -1.8% vs -1.3% NCT01809327
- -0.3% vs 0.0% NCT01032629
- -0.3% vs 0.0% NCT01032629
- -0.6% vs 0.1% NCT03170518
- -0.3% vs 0.7% NCT03170518
- -0.9% vs -0.7% NCT01106677
- -0.7% vs -0.6% NCT00968812
- -0.7% vs -0.7% NCT01106677
- -0.7% vs -0.6% NCT00968812
- -0.9% vs -0.2% NCT00642278
- -0.8% vs -0.2% NCT00642278
- -0.9% vs -0.2% NCT00642278
- -0.7% vs -0.2% NCT00642278
- -0.6% vs -0.0% NCT01340664
- -0.5% vs -0.0% NCT01340664
- -0.8% vs -0.2% NCT00642278
- -0.9% vs -0.0% NCT02025907
- -1.0% vs 0.1% NCT02220920
- -0.9% vs -1.1% NCT02622113
- 7.8% vs 8.3% NCT02964585
- Enavogliflozin
- -0.8% vs -0.8%avs dapagliflozinNCT04634500
Body weight, change (kg)
- Canagliflozin
- -2.9 vs -0.8−2.1 vs placeboNCT00642278
8 other results
- -1.5 vs 0.1 NCT01939496
- -2.3 vs -0.8 NCT00642278
- -1.0 vs 0.1 NCT01939496
- -2.9 vs -0.8 NCT00642278
- -2.3 vs -0.8 NCT00642278
- -2.0 vs -0.8 NCT00642278
- -3.5 vs -1.9 NCT02324842
- -6 vs -1.9 NCT02324842
- Enavogliflozin
- —Not posted · NCT05376969
HbA1c below 7%
- Canagliflozin
- 42.8% vs 43%vs Metformin XRNCT01809327
6 other results
- 38.8% vs 43% NCT01809327
- 56.8% vs 43% NCT01809327
- 49.6% vs 43% NCT01809327
- 57.1% vs 31.5% NCT01340664
- 47.8% vs 31.5% NCT01340664
- 32.3% vs 12.2% NCT02025907
- Enavogliflozin
- —Not posted · NCT05376969
Fasting plasma glucose, change
- Canagliflozin
- -0.6 vs 0.2−0.7 vs placeboNCT01032629
34 other results
- -0.4 vs 0.2 NCT01032629
- -1.1 vs 0.4 NCT01106651
- -0.7 vs 0.0 NCT01064414
- -1.8 vs 0.1 NCT01106690
- -1.7 vs 0.2 NCT01106625
- -1.9 vs 0.5 NCT01081834
- -0.1 vs -0.0 NCT01381900
- -1 vs 0.4 NCT01106651
- -0.8 vs 0.0 NCT01064414
- -1.5 vs 0.1 NCT01106690
- -1.0 vs 0.2 NCT01106625
- -1.5 vs 0.5 NCT01081834
- -0.1 vs -0.0 NCT01381900
- -1.9 vs 0.2 NCT02354235
- -1.9 vs -1.0 NCT01106677
- -1.7 vs -0.3 NCT01137812
- -2.1 vs -1.1 NCT01106677
- -1.4 vs -1.0 NCT01106677
- -1.5 vs -1.1 NCT01106677
- 9.7 vs 9.8 NCT02324842
- 10.0 vs 9.8 NCT02324842
- -1.4 vs 0.2 NCT00642278
- -1.3 vs -0.4 NCT01939496
- -1.4 vs 0.2 NCT00642278
- -0.0 vs -0.4 NCT01939496
- -1.3 vs 0.2 NCT00642278
- -1.5 vs 0.2 NCT00642278
- -0.9 vs 0.5 NCT01340664
- -0.9 vs 0.5 NCT01340664
- -0.9 vs 0.2 NCT00642278
- -1.6 vs -0.1 NCT02025907
- -1.9 vs -0.1 NCT02220920
- -1.8 vs -1.8 NCT02622113
- 7.9 vs 8.8 NCT02964585
- Enavogliflozin
- —Not posted · NCT05376969
3-point MACE (% with event)
- Canagliflozin
- —Not posted · NCT04304261
- Enavogliflozin
- —Not posted · NCT05376969
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Canagliflozin: 4 of 4 rows · Enavogliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Canagliflozin | Enavogliflozin |
|---|---|---|
| Dropout rate | 6.1%300 mga NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 72 more results7%100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 33.4%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 29%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.6%300 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 10.4%100 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 0.7%100 mg NCT02065791 · Phase 3 0% NCT02964585 · Phase 4 · registry result, not featured evidence —300 mg NCT03267576 · Phase 4 · registry result, not featured evidence 0% NCT02920918 · Phase 4 · registry result, not featured evidence 1.2% NCT01989754 · Phase 4 · registry result, not featured evidence 13.2% NCT02622113 · Phase 4 · registry result, not featured evidence · combination 11.3% NCT02227849 · Phase 4 · registry result, not featured evidence · combination 11.1% NCT02025907 · Phase 4 · registry result, not featured evidence 3.9% NCT02220920 · Phase 4 · registry result, not featured evidence · combination 3.6%300 mg NCT01939496 · Phase 4 · registry result, not featured evidence 5.3%100 mg NCT01939496 · Phase 4 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 4.3% NCT02354235 · Phase 3 · registry result, not featured evidence · combination 9.2%300 mg NCT01809327 · Phase 3 · registry result, not featured evidence 11%100 mg NCT01809327 · Phase 3 · registry result, not featured evidence 10.5%Canagliflozin 300 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 5.1%Canagliflozin 100 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 24.6%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 23.7%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 5.3%300 mg NCT01381900 · Phase 3 · registry result, not featured evidence 4%100 mg NCT01381900 · Phase 3 · registry result, not featured evidence 7.9%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 16.7%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 11.4%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 8%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 12%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 12.5%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 17.3%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 17.8%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 32.6%300 mg NCT01137812 · Phase 3 · registry result, not featured evidence 14%150 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 8.6%50 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 12.5%300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 7.8%100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 10.9%300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence 13.8%200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 7.8%50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 6.7%Canagliflozin NCT02324842 · Phase na · registry result, not featured evidence 13.3%Canagliflozin Plus Liraglutide NCT02324842 · Phase na · registry result, not featured evidence · combination | — |
| Discontinued due to AEs | —300 mga NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 72 more results—100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9.5%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.2%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —300 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 —100 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 —100 mg NCT02065791 · Phase 3 — NCT02964585 · Phase 4 · registry result, not featured evidence —300 mg NCT03267576 · Phase 4 · registry result, not featured evidence — NCT02920918 · Phase 4 · registry result, not featured evidence — NCT01989754 · Phase 4 · registry result, not featured evidence 5.3% NCT02622113 · Phase 4 · registry result, not featured evidence · combination 5.6% NCT02227849 · Phase 4 · registry result, not featured evidence · combination 0.9% NCT02025907 · Phase 4 · registry result, not featured evidence 1.3% NCT02220920 · Phase 4 · registry result, not featured evidence · combination 0%300 mg NCT01939496 · Phase 4 · registry result, not featured evidence 0%100 mg NCT01939496 · Phase 4 · registry result, not featured evidence 4.6% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 2.9% NCT02354235 · Phase 3 · registry result, not featured evidence · combination 2.9%300 mg NCT01809327 · Phase 3 · registry result, not featured evidence 1.3%100 mg NCT01809327 · Phase 3 · registry result, not featured evidence 3.4%Canagliflozin 300 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 1.7%Canagliflozin 100 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 9.7%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 3.7%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 3.1%300 mg NCT01381900 · Phase 3 · registry result, not featured evidence 2.7%100 mg NCT01381900 · Phase 3 · registry result, not featured evidence 2.2%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 4.4%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 3.5%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 0.9%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 1.6%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 4.9%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 5.1%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 5.1%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 5.6%300 mg NCT01137812 · Phase 3 · registry result, not featured evidence 7.5%150 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 1.1%50 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 3.1%300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 4.7%100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 3.1%300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.5%200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence —Canagliflozin NCT02324842 · Phase na · registry result, not featured evidence —Canagliflozin Plus Liraglutide NCT02324842 · Phase na · registry result, not featured evidence · combination | — |
| Serious AEs | 42.1%300 mga NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 72 more results41.6%100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9.7%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 5.4%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.7%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 5%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 5.9%300 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 10.4%100 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 33.5%100 mg NCT02065791 · Phase 3 0% NCT02964585 · Phase 4 · registry result, not featured evidence 0%300 mg NCT03267576 · Phase 4 · registry result, not featured evidence 17.6% NCT02920918 · Phase 4 · registry result, not featured evidence 24.6% NCT01989754 · Phase 4 · registry result, not featured evidence 9.3% NCT02622113 · Phase 4 · registry result, not featured evidence · combination 7% NCT02227849 · Phase 4 · registry result, not featured evidence · combination 1.9% NCT02025907 · Phase 4 · registry result, not featured evidence 4% NCT02220920 · Phase 4 · registry result, not featured evidence · combination 0%300 mg NCT01939496 · Phase 4 · registry result, not featured evidence 0%100 mg NCT01939496 · Phase 4 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 1.4% NCT02354235 · Phase 3 · registry result, not featured evidence · combination 2.9%300 mg NCT01809327 · Phase 3 · registry result, not featured evidence 1.7%100 mg NCT01809327 · Phase 3 · registry result, not featured evidence 1.7%Canagliflozin 300 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 3%Canagliflozin 100 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 18.2%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 3.4%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 16.6%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 4.1%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 1.8%300 mg NCT01381900 · Phase 3 · registry result, not featured evidence 2.2%100 mg NCT01381900 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 11.2%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 23.6%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 11.1%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 20%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 3.5%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 6.1%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 2.7%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 7.1%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 2.7%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 3.3%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 3.3%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 4.1%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 3.8%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 5.1%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence 3.2%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence 4.5%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence 2.3%300 mg NCT01081834 · Phase 3 · registry result, not featured evidence 1%300 mg NCT01081834 · Phase 3 · registry result, not featured evidence 2.5%300 mg NCT01081834 · Phase 3 · registry result, not featured evidence 0%100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 4.1%100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 5.6%100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 6.4%300 mg NCT01137812 · Phase 3 · registry result, not featured evidence 3.2%150 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 0%50 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 1.6%300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.5%200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 6.7%Canagliflozin NCT02324842 · Phase na · registry result, not featured evidence 0%Canagliflozin Plus Liraglutide NCT02324842 · Phase na · registry result, not featured evidence · combination | — |
| Most frequent reported AEs | 300 mga hypoglycaemia 14.6% (placebo 12.1%) nasopharyngitis 14.1% (placebo 15.3%) urinary tract infection 11% (placebo 8.9%) NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 59 more results100 mg nasopharyngitis 15.6% (placebo 15.3%) hypoglycaemia 12.5% (placebo 12.1%) upper respiratory tract infection 10.9% (placebo 11.3%) NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 300 mg nasopharyngitis 11.3% diarrhoea 8% upper respiratory tract infection 7.8% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 300 mg nasopharyngitis 7.6% diarrhoea 6.8% upper respiratory tract infection 5.6% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 100 mg nasopharyngitis 9.7% urinary tract infection 9.1% upper respiratory tract infection 7.5% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 100 mg nasopharyngitis 6.8% back pain 6% urinary tract infection 5.4% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 300 mg urinary tract infection 29.4% (placebo 4.6%) urinary tract infection 29.4% (placebo 4.6%) nausea 11.8% (placebo 1.1%) NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 100 mg headache 11.9% (placebo 3.4%) headache 11.9% (placebo 3.4%) nasopharyngitis 11.9% (placebo 5.7%) NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 100 mg hypoglycaemia 9.7% (placebo 10.3%) urinary tract infection 9.2% (placebo 8.4%) hypertension 6.5% (placebo 8.8%) NCT02065791 · Phase 3 300 mg fatigue 3.2% diarrhoea 1.6% discomfort 1.6% NCT03267576 · Phase 4 · registry result, not featured evidence acute kidney injury 17.6% hypotensive event 11.8% arrhythmic events 5.9% NCT02920918 · Phase 4 · registry result, not featured evidence balanoposthitis 3.2% (placebo 0.9%) NCT01989754 · Phase 4 · registry result, not featured evidence blood glucose decreased 40% (placebo 23.9%) hypoglycaemia 38.7% (placebo 32.8%) nasopharyngitis 34.7% (placebo 25.4%) NCT02622113 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 33.8% gastroenteritis 9.9% hypoglycaemia 9.9% NCT02227849 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 5.6% (placebo 5.6%) back pain 2.8% (placebo 0.9%) depression 2.8% (placebo 0%) NCT02025907 · Phase 4 · registry result, not featured evidence blood glucose decreased 26.7% (placebo 16.9%) hypoglycaemia 25.3% (placebo 21.1%) nasopharyngitis 16% (placebo 18.3%) NCT02220920 · Phase 4 · registry result, not featured evidence · combination 300 mg pollakiuria 5.4% (placebo 1.8%) nasopharyngitis 0% (placebo 0%) NCT01939496 · Phase 4 · registry result, not featured evidence 100 mg nasopharyngitis 5.3% (placebo 0%) pollakiuria 1.8% (placebo 1.8%) NCT01939496 · Phase 4 · registry result, not featured evidence nasopharyngitis 30.7% pollakiuria 6.5% constipation 5.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 18.6% (placebo 16.2%) NCT02354235 · Phase 3 · registry result, not featured evidence · combination 300 mg nasopharyngitis 3.8% upper respiratory tract infection 2.5% back pain 2.1% NCT01809327 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 3.8% glomerular filtration rate decreased 2.5% influenza 2.5% NCT01809327 · Phase 3 · registry result, not featured evidence diarrhoea 4.2% headache 3% influenza 3% NCT01809327 · Phase 3 · registry result, not featured evidence · combination diarrhoea 4.2% headache 3.8% influenza 3.4% NCT01809327 · Phase 3 · registry result, not featured evidence · combination 300 mg nasopharyngitis 18.6% (placebo 15.2%) hypoglycaemia 15.3% (placebo 19.8%) urinary tract infection 14.8% (placebo 8.9%) NCT01106651 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 9.7% (placebo 19.8%) nasopharyngitis 8.1% (placebo 15.2%) urinary tract infection 7.2% (placebo 8.9%) NCT01106651 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 18.7% (placebo 15.2%) hypoglycaemia 15.4% (placebo 19.8%) urinary tract infection 13.3% (placebo 8.9%) NCT01106651 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 10.4% (placebo 19.8%) nasopharyngitis 9.5% (placebo 15.2%) influenza 5.8% (placebo 7.6%) NCT01106651 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 7.5% (placebo 4%) upper respiratory tract infection 5.7% (placebo 6.2%) NCT01381900 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 9% (placebo 4%) upper respiratory tract infection 3.1% (placebo 6.2%) NCT01381900 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 11.2% (placebo 4.4%) nasopharyngitis 7.9% (placebo 11.1%) urinary tract infection 7.9% (placebo 5.6%) NCT01064414 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 22.5% (placebo 4.4%) urinary tract infection 13.5% (placebo 5.6%) nasopharyngitis 10.1% (placebo 11.1%) NCT01064414 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 14.4% (placebo 4.4%) arthralgia 4.4% (placebo 2.2%) bronchitis 4.4% (placebo 3.3%) NCT01064414 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 20% (placebo 4.4%) arthralgia 5.6% (placebo 2.2%) bronchitis 5.6% (placebo 3.3%) NCT01064414 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 9.6% (placebo 5.2%) pollakiuria 6.1% (placebo 0.9%) arthralgia 5.3% (placebo 1.7%) NCT01106690 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 13.2% (placebo 5.2%) arthralgia 7.9% (placebo 1.7%) urinary tract infection 7.9% (placebo 5.2%) NCT01106690 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 8% (placebo 6.1%) back pain 7.1% (placebo 2.6%) nasopharyngitis 5.3% (placebo 5.2%) NCT01106690 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 12.4% (placebo 6.1%) nasopharyngitis 9.7% (placebo 5.2%) back pain 8.8% (placebo 2.6%) NCT01106690 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 4.9% upper respiratory tract infection 4.9% urinary tract infection 3.5% NCT01106677 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 6.3% upper respiratory tract infection 6.3% urinary tract infection 4.6% NCT01106677 · Phase 3 · registry result, not featured evidence 100 mg pollakiuria 5.7% urinary tract infection 4.9% nasopharyngitis 4.1% NCT01106677 · Phase 3 · registry result, not featured evidence 100 mg urinary tract infection 7.3% pollakiuria 5.7% headache 5.2% NCT01106677 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 6.4% (placebo 3.2%) hypoglycaemia 5.8% (placebo 3.8%) nasopharyngitis 5.1% (placebo 2.6%) NCT01106625 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 7.1% (placebo 3.2%) hypoglycaemia 7.1% (placebo 3.8%) nasopharyngitis 5.8% (placebo 2.6%) NCT01106625 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 10.8% (placebo 6.4%) hypoglycaemia 7% (placebo 3.8%) urinary tract infection 5.7% (placebo 5.1%) NCT01106625 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 13.4% (placebo 6.4%) hypoglycaemia 8.3% (placebo 3.8%) urinary tract infection 7.6% (placebo 5.1%) NCT01106625 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 6.8% (placebo 5.2%) pain in extremity 6.8% (placebo 0%) urinary tract infection 4.5% (placebo 4.2%) NCT01081834 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 8.1% (placebo 5.2%) back pain 6.1% (placebo 3.1%) headache 6.1% (placebo 3.6%) NCT01081834 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 10.2% (placebo 5.2%) headache 8.6% (placebo 3.6%) back pain 7.6% (placebo 3.1%) NCT01081834 · Phase 3 · registry result, not featured evidence 100 mg urinary tract infection 6.4% (placebo 4.2%) nasopharyngitis 4.3% (placebo 5.2%) pain in extremity 2.1% (placebo 0%) NCT01081834 · Phase 3 · registry result, not featured evidence 100 mg headache 7.2% (placebo 3.6%) urinary tract infection 7.2% (placebo 4.2%) nasopharyngitis 5.1% (placebo 5.2%) NCT01081834 · Phase 3 · registry result, not featured evidence 100 mg headache 9.7% (placebo 3.6%) urinary tract infection 8.2% (placebo 4.2%) nasopharyngitis 7.2% (placebo 5.2%) NCT01081834 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 17.5% nasopharyngitis 8.8% upper respiratory tract infection 8.8% NCT01137812 · Phase 3 · registry result, not featured evidence 300 mg daily headache 4.7% (placebo 3.1%) nausea 4.7% (placebo 0%) abdominal pain upper 3.1% (placebo 1.5%) NCT00642278 · Phase 2 · registry result, not featured evidence 100 mg daily headache 7.8% (placebo 3.1%) urinary tract infection 3.1% (placebo 6.2%) vulvovaginal mycotic infection 3.1% (placebo 0%) NCT00642278 · Phase 2 · registry result, not featured evidence 300 mg twice daily nausea 7.8% (placebo 0%) abdominal pain upper 6.3% (placebo 1.5%) urinary tract infection 4.7% (placebo 6.2%) NCT00642278 · Phase 2 · registry result, not featured evidence 200 mg daily urinary tract infection 9.2% (placebo 6.2%) vulvovaginal mycotic infection 6.2% (placebo 0%) headache 3.1% (placebo 3.1%) NCT00642278 · Phase 2 · registry result, not featured evidence 50 mg daily nasopharyngitis 7.8% (placebo 3.1%) vulvovaginal mycotic infection 6.3% (placebo 0%) nausea 4.7% (placebo 0%) NCT00642278 · Phase 2 · registry result, not featured evidence urinary frequency increased 86.7% dry mouth 26.7% light-headedness/dizziness 26.7% NCT02324842 · Phase na · registry result, not featured evidence nausea 53.3% dry mouth 40% constipation 33.3% NCT02324842 · Phase na · registry result, not featured evidence · combination | — |
Notes
- aPopulation comparability has not been reviewed for 65 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Canagliflozin
show 1 more result
show 2 more results
show 2 more results
show 34 more results
show 33 more results
show 1 more result
+ 42 further endpoints in the CSV export.
Chronic Kidney Disease
Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline
Canagliflozin · Invokana
Marketed by Johnson & Johnson and partners
NCT02065791 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 4,401 participants with type 2 diabetes and diabetic nephropathy. Canagliflozin significantly lowered the rate of the composite renal/cardiovascular endpoint (kidney failure, doubling of creatinine, or renal/CV death) compared with placebo, with a hazard ratio of 0.70.
Next expected readout: December 2026 · NCT05507892 (registry estimate)
Reported efficacy
Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104: Incidence of 30% eGFR decline at week 104: 18.2% canagliflozin vs 29.5% placebo; intergroup difference (placebo-canagliflozin) 11.3% (95% CI 1.2-21.5, P=0.029) (met)
Result source: NCT03436693
Enavogliflozin · Envlo
Marketed by Daewoong Pharmaceutical and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Canagliflozin | Enavogliflozin |
|---|---|---|
| Kidney composite outcome | —Not reported | —Trial running · NCT06606093 |
| UACR, % change | 0.6% vs 1.2%−0.6 vs placeboNCT03436693 | —Trial running · NCT06606093 |
| eGFR slope | —Not reported | —Trial running · NCT06606093 |
| Haemoglobin, change | —Not reported | —Trial running · NCT06606093 |
Kidney composite outcome
- Canagliflozin
- —Not reported
- Enavogliflozin
- —Trial running · NCT06606093
UACR, % change
- Canagliflozin
- 0.6% vs 1.2%−0.6 vs placeboNCT03436693
- Enavogliflozin
- —Trial running · NCT06606093
eGFR slope
- Canagliflozin
- —Not reported
- Enavogliflozin
- —Trial running · NCT06606093
Haemoglobin, change
- Canagliflozin
- —Not reported
- Enavogliflozin
- —Trial running · NCT06606093
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Enavogliflozin: no structured comparison results are available for Chronic Kidney Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Canagliflozin: 4 of 4 rows · Enavogliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Canagliflozin |
|---|---|
| Dropout rate | 0.7%100 mga NCT02065791 · Phase 3 show 1 more result19.5%100mg NCT03436693 · Phase 3 |
| Discontinued due to AEs | —100 mga NCT02065791 · Phase 3 show 1 more result14.3%100mg NCT03436693 · Phase 3 |
| Serious AEs | 33.5%100 mga NCT02065791 · Phase 3 show 1 more result27.9%100mg NCT03436693 · Phase 3 |
| Most frequent reported AEs | 100 mga hypoglycaemia 9.7% (placebo 10.3%) urinary tract infection 9.2% (placebo 8.4%) hypertension 6.5% (placebo 8.8%) NCT02065791 · Phase 3 show 1 more result100mg nasopharyngitis 35.1% (placebo 37%) hypoglycaemia 21.4% (placebo 20.8%) blood glucose decreased 17.5% (placebo 14.9%) NCT03436693 · Phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Canagliflozin
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Canagliflozin's landscape · Enavogliflozin's landscape